Owen L. Woodman
Owen L. Woodman received his B.S. and Ph.D. degrees from the University of Melbourne, Victoria, Australia, in 1977 and 1981, respectively. He has been a Professor and the Head of the Discipline of Cell Biology and Anatomy at the School of Medical Sciences at RMIT University, since May 2007, after more than 20 years at the University of Melbourne, predominantly at the Department of Pharmacology. He has more than 30 years of experience in researching cardiovascular physiology and pharmacology with a particular focus on endothelial control of vascular function and pathological influences on vascular reactivity, especially the effects of diabetes, ischaemia and reperfusion, and atherosclerosis. In his search for pharmacological approaches to preserve endothelial function in pathological states, he has developed a special interest in using flavonoids, such as flavonols, isoflavones, and catechins, as a basis to the discovery and development of novel compounds to treat cardiovascular disease. This has led to significant scientific and commercial outcomes. With his colleagues at the Howard Florey Institute (Clive May, Bevyn Jarrott, and Greg Dusting), he is a founding scientist of Neuprotect Pty Ltd, a startup company with the aim to develop novel flavonols for the treatment of myocardial ischemia. He is a Fellow of the American Heart Association and an active Member of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, the Australian Physiological Society, and the High Blood Pressure Research Council of Australia amongst other societies, and he is an Editor (Vascular) at the Clinical and Experimental Pharmacology and Physiology journal.
Biography Updated on 16 January 2012